Genomic Vision to demonstrate 'molecular combing' technology's ability to identify novel cancer-causing BRCA gene variants
14 Janvier 2016 - 7:25PM
Business Wire
Quest Diagnostics to aid analysis of study on
up to 1,000 de-identified patient specimens
Regulatory News:
Genomic Vision (Paris:GV) (GV: EN Paris), a molecular
diagnostics company specializing in the development of diagnostic
tests for genetic diseases and cancers based on molecular combing
technology, today announced its plans to initiate a patient study
to demonstrate the value of Genomic Vision’s FiberVision® molecular
combing technology in detecting novel BRCA gene variants
associated with a predisposition to breast and ovarian cancer.
Quest Diagnostics (NYSE: DGX), a strategic collaborator of
Genomic Vision, plans to support the study, which will seek to
determine the extent to which molecular combing can identify BRCA
gene variants missed by other test methods. The analysis will be
conducted at Quest’s advanced clinical laboratory in San Juan
Capistrano, Calif. and at Genomic Vision’s laboratories in France.
The study is expected to begin this month and be completed over the
summer 2016. It is expected to involve testing on 500 to 1,000
de-identified specimens.
Loss of function variants of the BRCA1 and BRCA2 genes
significantly increase a person’s inherited risk of developing
breast, ovarian and certain other cancers. Clinical laboratories
use DNA sequencing combined with either microarray or multiplex
ligation-dependent probe amplification (MLPA) to identify these
variants. Scientists at Genomic Vision and Quest Diagnostics
believe molecular combing is able to identify large genomic
re-arrangements that conventional methods fail to identify.
”Next generation sequencing is a hugely important innovation
that has radically improved the detection of genetic variants
involved in cancer. But it has its limitations, particularly for
detecting large genomic rearrangements,” states Dr. Charles
(Buck) Strom, Medical Director of Quest Diagnostics Nichols
Institute. “Our goal for this study is to understand the
capabilities of molecular combing in detecting these types of
uniquely complex genetic variants. The findings will help inform
our understanding of the clinical value of molecular combing and
the potential opportunities for a BRCA molecular combing
lab-developed test for patients and physicians in the United
States.”
Dr. Camille Chypre, Genomic Vision’s VP Research &
Development, comments: “We are very excited about this study
that will assess the role of structural variations in the
development of breast and ovarian cancer. Molecular combing has a
potential to detect with accuracy the hereditary predisposition to
this pathology in high risk patients.”
Aaron Bensimon, Ph.D., Genomic Vision’s co-founder and
Chairman, comments: “The decision to run this clinical study
came out from the common will of Quest Diagnostics and Genomic
Vision to maximize the success of the launch of Quest’s
lab-developed test in the US market. Molecular combing is a
uniquely advanced technology, and developing support for its
clinical value in BRCA gene variant detection is an important
element in our strategy.”
Genomic Vision and Quest Diagnostics have a strategic agreement
under which Quest retains exclusive rights to develop, validate and
market tests based on molecular combing in the fields of breast and
ovarian cancer, such as BRCA gene mutation testing, as well as
hereditary colon cancer (Lynch syndrome), spinal muscular atrophy
(SMA) and facioscapulohumeral muscular distrophy (FSHD), in the
United States, India and Mexico. In 2014, Quest Diagnostics
introduced a molecular combing FSHD lab-developed test to
physicians in the United States.
Quest Diagnostics is a leader in genetic, cancer and women's
health diagnostics. The company provides a suite of tests for
identifying gene variants involved in germline (genetic) cancers
and somatic tumors under the BRCAvantage™ and OncoVantage™ brand
names.
●●●
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a molecular diagnostics
company that specializes in the development of diagnostic tests for
genetic diseases and cancers based on molecular combing. Using this
innovative technology that allows the direct visualization of
individual DNA molecules, Genomic Vision detects quantitative and
qualitative variations in the genome that are at the origin of
numerous serious pathologies. The Company is developing a solid
portfolio of tests that initially target breast and colon cancers.
Since 2013, the Company has marketed the CombHelix FSHD test for
identifying facioscapulohumeral dystrophy (FSHD), a myopathy that
is difficult to detect. It is marketed in the United States through
a strategic alliance with Quest Diagnostics, the American leader in
diagnostic laboratory tests, and in France directly by the Company.
Genomic Vision has been listed on Compartment C of Euronext Paris
since April 2014.
ABOUT MOLECULAR COMBING
DNA molecular combing technology significantly improves the
structural and functional analysis of DNA molecules. DNA fibers are
stretched over glass slides, as if "combed", and uniformly aligned
over the entire surface. It is then possible to identify genetic
anomalies by locating specific genes or sequences in the patient's
genome using genetic markers, a technique developed by Genomic
Vision and patented under the name Genomic Morse Code. This
exploration of the entire genome at high resolution via a simple
analysis enables the direct visualization of genetic anomalies that
are undetectable by other technologies.
For further information, please go to: www.genomicvision.com
Member of CAC® Mid & Small, CAC®
All-Tradable and EnterNext© PEA-PME 150 indexes
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160114006145/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorLHAInvestor Relations
USAnne Marie Fields, SVP,
212-838-3777afields@lhai.comorNewCapInvestor Relations /
Strategic CommunicationsDušan Orešanský / Emmanuel Huynh, +33 1 44
71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024